Contact an Axogen rep

Use this form to get in contact with a rep or call 888.Axogen1 (888-296-4361) to
learn about Avance. We look forward to speaking with you.

Contact Axogen

If you’re a healthcare professional, use this form to get in contact with the Axogen team.

Complete the fields below and submit. We’d love to hear from you.

*Indicates required field.

 
MAT-US-AVAN-0014 V1.0
Important safety information

Important Safety Information

Indications

AVANCE® is an acellular nerve scaffold indicated for the treatment of adult and pediatric patients aged one month and older with:

  • Sensory nerve discontinuity (≤25 mm)
  • Sensory nerve discontinuity (>25 mm); Approved under accelerated approval based on static two-point discrimination (s2PD) at 12 months in sensory nerve gaps ≤25 mm, which reasonably predicts clinical benefit. Continued approval may be contingent upon confirmatory clinical trial results.
  • Mixed and motor nerve discontinuity; Approved under accelerated approval based on s2PD outcomes in sensory nerves; continued approval may be contingent upon confirmatory clinical trial results.

Warnings and Precautions

  • Procedural Complications: Monitor for procedural complications, including pain, hyperesthesia, infection, implant site swelling, adhesions, hypertrophic scar formation, impaired motor or sensory function, bleeding, and neuroma formation, and manage accordingly.
  • Transmission of Infectious Diseases: Because AVANCE is made from human donor tissue, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. All infections thought to be transmitted by AVANCE should be reported to Axogen Corporation at 1-888-296-4361.

Adverse Reactions

The most common adverse reactions (≥2%) were procedural pain (4%) and hyperesthesia (3%). A serious adverse reaction (wound dehiscence) occurred in 1 patient.